Navigation Links
ExonHit Therapeutics - 2007 Financial Results
Date:3/5/2008

p>Increase (decrease) in cash from:

Inventory (42) (27)

Accounts receivable (1,392) 706

Grants receivable 112 16

Research tax credit receivable 1,603 1,449

Accounts payable

and accrued expenses (98) 463

Accrued compensation 235 (16)

Other current liabilities - -

Prepaid expenses and other assets (403) (61)

Deferred income, short term 1,076 (240)

Deferred income, long term (860) (372)

Net cash used in operating activities (3,940) (4,934)

INVESTING ACTIVITIES

Purchase of property and equipment (757) (1,051)

Payment of patent and acquisition

of other intangibles 416 174

Net cash used in investing activities (340) (877)

FINANCING ACTIVITIES

Proceeds from loans 13,522 -

Repayment of loans and capital lease (414) 345

Issuance of shares (net of fees) 1,585 12,977

Net cash provided by (used in)

financing activities 14,693 13,322

Net increase (decrease) in cash

and cash equivalents 10,413 7,511

Effects of exchange rate on cash (41) (141)

Cash and cash equivalents, beginning of period 13,601 23,972

Cash and cash equivalents, end of period 23,972 31,342 <
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 ... today announced its financial results for the second ...  sales grew nearly 300% as compared to the ... first launched," said Roger Jeffs, Ph.D., United Therapeutics, ... Orenitram sales was due to an increase in ...
(Date:7/28/2015)... July 28, 2015  Faced with increasing challenges ... palliative rather than symptomatic, the global healthcare industry ... therapies capable of curing or significantly changing the ... to look towards regenerative medicine as a viable ... paradigm in human health with the potential to ...
(Date:7/27/2015)... and FRANKLIN, Tenn. ... a privately-owned  premier provider of health care services ... in the U.S., today announced that its parent ... signed a definitive agreement with Medical Properties Trust, ... acquisition of Capella for $900 million in cash.  The transaction ...
(Date:7/27/2015)... ... 27, 2015 , ... This is a professional and in-depth ... overview of the industry including definitions, classifications, applications and industry chain structure. The ... landscape analysis, and key regions development status. Development policies and plans are discussed ...
Breaking Biology Technology:United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3
... , ... Centage extends its financial performance management offerings to bring powerful, dynamic, driver-based planning, ... ... 2009 -- Centage Corporation, a leading provider of integrated budgeting, forecasting, consolidation and ...
... BOZEN, Italy, August 10 , ... Health Robotics today announced that it ... Robotics, CytoCare Robot. The,agreement enables McKesson to achieve its goal ... admixtures. , "We are very pleased ...
... LEXINGTON, Mass. and HEIDELBERG, Germany, Aug. 10 ... DNA-capture method, HybSelect(TM), to re-sequence the exons of genes involved ... the ultimate goal of developing genetic tests to detect carrier ... , In this collaboration the NCGR will bring ...
Cached Biology Technology:Centage Corporation Announces Planning Maestro Business Performance Management Software for Mid-Market Enterprises 2Centage Corporation Announces Planning Maestro Business Performance Management Software for Mid-Market Enterprises 3McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 2McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 3The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 2The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 3
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/25/2015)... , June 25, 2015 ... Sensors Market by Type (Swipe & Area), Technology, Material ... Government, Healthcare, Commercial Security & Others) & Geography ... by marketsandmarkets, the said market is expected to ... of 17.1%. Browse 76 market ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... most common congenital defects in humans it is ... antenatal sonography is a kidney abnormality known as ... the kidney to the bladder is impeded. By studying ... the Hospital for Sick Children, Toronto, have identified a ...
... Cross-disciplinary teams of scientists studying genetic pathways that ... also cause certain forms of congenital heart disease ... muscle that is the leading cause of sudden death ... mutations into mice and successfully treated HCM in the ...
... having an effect on the safety of the world,s food ... get worse, a Michigan State University professor told a symposium ... Advancement of Science. Ewen Todd, an MSU professor of ... Climate Change Affects the Safety of the World,s Food Supply" ...
Cached Biology News:Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Fas-ligand rabbit polyclonal antibody...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
Biology Products: